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ABSTRACT: Background: Acute graft-versus-host disease (GVHD) 
usually occurs by 8 weeks after liver transplantation (LT) usually is 
an uncommon complication but has both high mortality and major 
diagnostic challenge in addition most of them are associated with 
resistance to steroid therapy. Objective: Discuss the pathogenesis, 
treatment and long-term results of Acute Graft versus Host Dis-
ease after Liver Transplantation. Methods: A PubMed search was 
performed to identify all reported cases of GVHD following LT. The 
medical subject heading GVHD disease was used in combination 
with LT, including adults (19 + years) and children. The bibliog-
raphies of the articles found though PubMed were then searched 
for further reports of GVHD. Results: We reviewed 102 cases of 
acute GVHD, 96 (94.1%) adults and 6 (5.8%) children. After treat-
ment 24 (25%) adults and 3 (50%) children were alive only. As far 
as the treatment of GVHD is concern the therapy used in adults 
and in children patients was respectively : anti-thymocyte globulin 
+ prednisolone – 19 (19.5%); interleukin-2 receptor blocker – 17 
(17.5%); OKT3 – 12 (12.3%); cyclosporine – 9 (9,2% ); others – 
39 (40.2%) and  in children anti-thymocyte globulin – 1 (20%); 
anti-thymocyte globulin + prednisolone – 1 (20%); prednisolone 
– 1 (20%); anti-thymocyte globulin + prednisolone + interleukin-2 
receptor blocker-1 (20%); not mentioned – 1.There was no standard 
treatment of acute GVHD for both children and adults. Conclusion: 
Although acute GVHD following LT is rare complication and mor-
tality is still very high, there is no consensus for the treatment of 
steroid-refractory forms. Further researches are needed to provide 
new approach for treating effectively such condition.
KEYWORDS: Liver transplantation; Graft vs host disease/etiology; 
Grafts vs host disease/therapy; Pathogenesis/treatment; Steroids/
therapeutic use. 
RESUMO: Introdução: A forma aguda da doença do enxerto contra 
o hospedeiro ocorre geralmente até oito semanas após o transplan-
te de fígado, é rara, porém tem mortalidade alta e constitui-se em 
um grande desafio terapêutico principalmente naqueles casos que 
são resistentes ao tratamento com corticóides. Objetivo: Discutir 
a patogênese, tratamento e resultados a longo prazo da Forma 
Aguda da Doença Enxerto contra o Hospedeiro após Transplante 
de Fígado. Métodos: Fizemos uma pesquisa na base de dados 
do PubMed procurando identificar todos os casos de doença En-
xerto contra o Hospedeiro após Transplante de Fígado incluindo 
adultos com mais de 19 anos e crianças. Resultados: Revisamos 
102 casos desta doença e encontramos 96 (94,1%) adultos e 6 
(5,8%) crianças. Após o tratamento, 24 (25%) adultos e 3 (50%) 
crianças estavam vivos. Com relação ao tratamento da doença do 
enxerto contra o hospedeiro em adultos e crianças encontramos 
respectivamente: globulina anti-timocítica + prednisolona – 19 
(19,5%); bloqueador do receptor da interleucina 2 – 17 (17,5%); 
OKT3 – 12 (12,3%); ciclosporina – 9 (9,2%); outros – 39 (40,2%) 
e em crianças globulina anti-timocítica – 1 (20%); globulina anti-
timocítica + prednisolona – 1 (20%); prednisolona – 1 (20%); glo-
bulina anti-timocítica + prednisolona + bloqueador do receptor da 
interleucina 2 -1 (20%); não mencionado – 1. Conclusão: Pesquisas 
devem ser aprofundadas nos mecanismos que desencadeiam esta 
patologia. Não existe consenso para o tratamento da doença do 
enxerto contra o hospedeiro após o transplante de fígado naqueles 
doentes que são refratários ao uso de esteróides.
DESCRiTORES: Transplante de fígado; Doença enxerto-hospe-
deiro/etiologia; Doença enxerto-hospedeiro/terapia; Patogênese/
tratamento; Esteróides/uso terapêutico.
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iNTRODUCTiON 
Acute graft-versus-host disease (GVHD) usually occurs by 8 weeks after liver 
transplantation (LT)1, and its prevalence has been 
estimated to be 0.3 to 1.9%8,45,56,58.
Acute GVHD following LT is an uncommon 
complication but has both high mortality and major 
diagnostic challenge and in addition to that most 
of them are associated with resistance to steroid 
therapy.
We reviewed 102 cases of acute GVHD in the 
past 23 years, discussing the pathogenesis, treatment 
and long-term results of this condition after LT.
METHODS
A PubMed search was performed to identify 
all reported cases of GVHD following LT. The 
medical subject heading GVHD disease was used 
in combination with LT, including adults (19 + years) 
and children. The bibliographies of the articles found 
though PubMed were then searched for further reports 
of GVHD.
The mean age of affected patients was 52 years 
in 96 adult patients and 5 years in 6 children. The 
onset of GVHD was similar in both groups, averaging 
approximately 1 month after LT for both adults and 
children. The clinical manifestations of GVHD were 
similar in both adult and children and consist of 
rash, fever, diarrhea and bone marrow involvement 
manifested by cytopenias.
RESULTS
We reviewed 102 cases of acute GVHD, 96 
(94.1%) adults and 6 (5.8%) children. The primary 
difference seen between pediatric and adults patients 
was in mortality with 75% death rate in reported 
adult patients with GVHD vs. a 50% mortality rate for 
patients younger than 18 years. Of the 102 patients 
reported to have experienced of GVHD, only 27 were 
reported to be alive at the time of publication of their 
case (Table 1). 94 (92.15%) patients demonstrating 
chimerism for confirming the diagnosis of GVHD 
after LT.
Table 1. Literature review. Acute graft vs host disease after liver transplantation. Treatment and results
Reference Patients Basic iS Onset Chimerism Therapy Outcome
Burdick et al. (1988)5 1 CsA,AZA,PSL 21 + ATG, PSL Alive
Bhaduri et al. (1990)3   1 child AZA, PSL 23 + ATG, PSL Dead
Marubayashi et al. (1990)36 1 CsA,AZA,PSL 13 + ATG, PSL Dead
Merle et al. (1990)39 1 - 30 + Anti-IL2R Dead
Jamieson et al. (1991)25 2 CsA,PSL,AZA,IL2-R blocker 18 / 30 + CsA, PSL, ATG 1x dead
Roberts et al. (1991)64 4 CsA,AZA,PSL 18-42 ND 3x IS increase with PSL 4x dead
Comenzo et al. (1992)13   1 child CsA,PSL 95 + IS increase Alive
Collins et al. (1992)12 1 CsA,AZA,PSL 35 + PSL Dead
De Paoli et al. (1992)15 1 - 14 + ATG, PSL Dead
Joysey et al. (1992)27 1 - 38 + ATG, PSL Dead
Mazzaferro et al. (1993)37 1 CsA,PSL 17 + PSL Dead
Rosen et al. (1993)51 1 - 24 - Anti L-AB Dead
Redondo et al. (1993)49 1 - 25 + OKT3, PSL Alive
Neumann et al. (1994)40 1 CsA,AZA,PSL 32 + ATG, OKT3 Dead
Cattral et al. (1994)9 1 child CsA,PSL 16 + PSL Alive
Pageaux et al. (1995)42 1 CsA,AZA,PSL 18 + ATG, PSL Dead
Connors et al. (1996)14 1 FK506,PSL 24 + - Dead
Sanchez et al. (1996)52 1 CsA,AZA,PSL 34 + OKT3 Dead
Whitington et al. (1996)68 1 child CsA,AZA,PSL 34 + ATG Alive
Burt et al. (1996)6 1 - 28 + PSL Dead
Continua
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Kiuchi et al. (1998)31 1 child - 27 + - Dead
Aziz et al. (1998)2 1 CsA,AZA,PSL 15 - ATG Alive
Paizis et al. (1998)41 1 - 21 + OKT3 Alive
Schmuth et al. (1999)55 1 FK506,PSL 7 + AZA, PSL Dead
Joseph et al. (1999)26 1 CsA,AZA,PSL 35 + CsA, Cyclophosphamide Dead
Merhav et al. (1999)39 1 FK506,PSL 30 + CsA, PSL, ATG Dead
Hahn et al. (2000)20 2 CsA,PSL/ FK506,PSL 35 / 21 + OKT3 / Stop IS Dead /Alive
Au et al. (2000)1 1 FK506,PSL 20 + AZA,PSL Dead
Hanaway et al. (2001)21 1 - 18 - ATG,PSL Dead
Romognoulo et al. (2000)50 1 PLS, CsA 23 - AZA,PSL Dead
Knox et al. (2002)33 1 FK506,MMF,PSL 17 + PSL Alive
Lehner et al. (2002)34 1 MMF, IL-2R 21 + Stop IS Alive
Smith et al. (2003)56 13 FK506,AZA,PSL 8-115 + IS increase PSL, GM-CSF 12x dead
Sudhindran et al. (2003)59 2 FK506, PSL, AZA 24 / 31 + PSL, IL-2R Blocker Alive / Dead
Soejima et al (2004)57 4 CsA,PSL,FK506 27-114 + IS increase FK506, PSL, CsA, ATG 2x Dead
Key et al. (2004)30 7 FK506,AZA,PSL 14-56 + IS increase PSL, ATG,  IL-2R Blocker 5x Dead
Hara et al. (2004)22 1 CsA,PSL 20 + Change CsA to FK506, ATG Dead
Walling et al. (2004)66 1 FK506,PSL 70 + MMF, PSL Alive
Pollack et al. (2005)47 1 FK506,MMF,PSL 240 + OKT3, SCT Dead
Kamei et al. (2006)28 8 - 14-114 - - 8x Dead
Sun et al. (2006)560 1 FK506, MMF, PSL 122 + PSL Dead
Schappi et al. (2006)54 1 child MMF, FK506, PSL, IL2-R Blocker 1 +
IL-2R Blocker, 
Alemtuzumab, ATG, PSL Dead
Ghali et al. (2007)17 1 IL2-R Blocker, MMF, and PSL, FK506 ND +
ATG, PSL, IL-2R Blocker, 
G-CSF, Erythropoietin Dead
Chinnakotta et al. (2007)10 3 2x MMF, FK506, PSL / 1x CsA, PSL, RAPA 07-70 + Stop IS 2x Alive
Perri et al. (2007)45 5 Standard IS 23-35 + PSL, ATG and IL-2R 5x Dead
Wang et al. (2007)67 2 FK506, PSL, MMF / CsA, PSL 24 / 32 ND PSL, GM-CSF Dead /Alive
Cho et al. (2007)11 1 FK506, PSL 56 + IS increase Dead
Guo et al. (2008)19 2 FK506,PSL 40-59 + PSL 2x Dead
Kohler et al. (2008)32 5
1x IL2-R 
Blocker,CSA,AZA,PSL / 
4x PSL,FK506
20-60 + ATG, OKT3 / PSL, ATG / PSL, ATG / PSL 5x Dead
Thin et al. (2008)63 1 PSL,FK506, AZA 20 + GM-CSF, PSL, CsA, MMF, Etanercept Alive
Grosskreutz et al. (2008)18 1 FK506,PSL 45 + PSL Alive
Lu et al. (2008)35 1 Radiosone, PSL, FK506 18 ND Stop IS, Thymosin Alpha 1, ATG, IL-2R Blocker Alive
Stotler et al. (2009)58 1 - 20 + Alefacept Alive
Piton et al. (2009)46 1 FK506,PSL 21 + PSL,ATG, Infliximab Alive
Gao et al. (2010)16 1 FK506 9 ND decreased FK506 Alive
Chaib et al. (2011)7 1 FK506,PSL   31 + ATG, PSL Dead
Legenda: IS: Immunosuupression; CsA: Cyclosporine; AZA: Azathioprin; PSL: Prednisolone; FK506: Tacrolimus; MMF: Mycophenolate Mofetil; RAPA: Rapamycin; IL-2R 
Blocker, Interleucin-2 Receptor Blocker; ATG: Anti-Thymocyte Globulin; SCT: stem cell transplantation; GM-CSF: Granulocyte Macrophage Colony Stimulating Factor; 
ND: Not Described.
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The literature describes several approaches 
used to treat GVHD after LT. These involve the use 
of available immunossupressive medications and of 
biological agents aimed at modulating the pathogenic 
lymphocytes.
Basic immunossupression used  in adults and 
children patients after LT was respectively: FK506 
+ prednisolone – 49 (50.5%); cyclosporine + pred-
nisolona + azathioprine – 19 (19,5%); cyclosporine 
+ prednisolone – 5 (5.1%); others – 23 (23.7%); and 
cyclosporine + prednisolone – 2 (40%); cyclosporine 
+ prednisolone + azathioprine – 1(20%); FK506 + 
prednisolone – 1 (20%); azathioprine + prednisolone 
– 1 (20%); not mentioned – 1 (20%).
As far as the treatment of GVHD is concern the 
therapy used in adults and in children patients was 
respectively: anti-thymocyte globulin + prednisolone 
– 19 (19.5%); interleukin-2 receptor blocker – 17 
(17.5%); OKT3 – 12 (12.3%); cyclosporine – 9 (9.2%); 
others – 39 (40.2%) and anti-thymocyte globulin – 1 
(20%); anti-thymocyte globulin + prednisolone – 1 
(20%); prednisolone – 1 (20%); anti-thymocyte globu-
lin + prednisolone + interleukin-2 receptor blocker-1 
(20%); not mentioned – 1.
DiSCUSSiON
Acute GVHD after LT was first described by 
Burdick et al.6, occurs when immunocompetent donor 
lymphocytes originating from the transplanted liver 
undergo activation and clonal expansion, allowing 
them to mount a destructive cellular immune response 
against recipient tissues.
The essential requirements for development of 
GVHD was described by Billigham as early as 19664; 
first the graft must contain immunologically competent 
cells; second, the recipient must be recognized as 
foreign by the graft; and third the recipient must be 
unable to reject the graft before it mounts an effective 
immune response.
The aim of therapy for GVHD after LT is to allow 
the elimination of the unwanted donor lymphocytes by 
the host immune system. Many drugs and antibodies 
have been used in the past years such as: corticos-
teroids (increased or decreased immunossupression); 
anti-lymphocyte therapy (antithymocyte globulin, 
antilymphocyte globulin and the monoclonal anti-
lymphocyte agent OKT3); anti-interleukin-2 receptor 
antibodies (the humanized antibody daclizumab and 
the murine/human chimeric monoclonal antibody 
basiliximab) and others like infusion of host immune 
cells or autologus bone marrow transplant.
The literature describes 28 adult patients treat-
ed primarily with corticosteroids and/ or an increased 
in standard immunosuppressive medications after the 
diagnosis of GVHD after LT30,55,56,64. Of these patients 
all were reported to die of complications of GVHD 
with the exception of one who was reported to be 
alive only 11 days after therapy was initiated. On the 
basis of the above results it is evident that treatment 
of GVHD after LT exclusively with corticosteroids or 
increase in immunosupression is inadequate long-
term therapy.
There have been 37 adult patients reported to 
have been treated with ATG or OKT3. Of these only 
7 (18,9%) patients were reported to be alive  at least 
> 8 months after LT2,5,15,21,22,25,27,30,32,35,38,40-42,45-47,49,52,57.
Of course this represents an improvement over 
results that use corticosteroids therapy alone, survival 
is still poor and the development of a complication 
of immunosupression such as posttransplantation 
proliferative disease raises the concern.
There have been 17 adult patients reported to 
have been treated with anti-interleukin-2 receptor anti-
bodies Of these only 5 (29,4%) patients were reported 
to be alive after LT17,30,35,45,59,63. Main complication of 
using these agents are sepsis, pancytopenia and 
gastrointestinal bleeding.
Six adult patients have been reported to have 
been primarily treated for GVHD after LT by a reduc-
tion or discontinuation of immunossupression7,47,61. 
Five of these patients were reported to be alive at the 
time of report with their recovery attributed to reduc-
tion in immunosupression. The theoretical benefit 
of this approach is that by reducing or discontinuing 
immunosupression, the host immune system may be 
enabled to rejected the donor lymphocytes mediating 
the GVHD56.
The largest series of GVHD after LT reported 
in this review  was from Smith et al.4 and Key et al.30 
13 and 7 adults patients respectively. The basic im-
munossupression after LT was very much the same 
in the two groups, FK506, azathioprine and predniso-
lone. The treatment of GVHD was basically increase 
of prednisolone associated with GM-CSF and inter-
leukin-2 receptor blocker in the former and the latter 
respectively.  All of patients but one56 have died after 
the treatment of this condition for different reasons, 
demonstrating clearly that there was no standard 
treatment of acute GVHD so far. The most popular 
treatment in 96 adults patients were stop immunosu-
pression, prednisolone and anti-thymocyte globulin. 
Also there is no consensus to date for treating steroid-
refractory forms of acute GVHD after LT.
Finally, since TNF-alpha is secreted by mono-
cytes and macrophages leading to donor T-cell 
activation and inducing a cascade of inflammatory 
cytokine and cell activation in acute GVHD following 
LT the use of infliximab (a chimerical mouse/human 
immunoglobulin G antibody directed against soluble 
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and transmembrane forms of human TNF-alpha) 
has been successfully reported in treatment of this 
condition46.
In conclusion, although acute GVHD following 
LT is rare complication and mortality is still very high, 
there is no consensus for the treatment of steroid-
refractory forms. Further researches are needed to 
provide new approach for treating effectively such 
condition.
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